-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Chronic Obstructive Pulmonary Disease (COPD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLS-0071 in Hypoxic-Ischemic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLS-0071 in Hypoxic-Ischemic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLS-0071 in Hypoxic-Ischemic Encephalopathy Drug Details: RLS-0071 (PIC1-01) is under development...
-
Product Insights
NewHypoxic-Ischemic Encephalopathy – Drugs In Development, 2024
Empower your strategies with our Hypoxic-Ischemic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Hypoxic-ischemic encephalopathy (HIE) is also known as neonatal encephalopathy, perinatal hypoxia, or birth asphyxia. It is a serious birth complication affecting full-term infants less commonly seen in childhood and adulthood. It is caused by loss of oxygen or reduced blood flow to the brain cells. The exact cause of HIE is unknown but brain dysfunction is observed in patients with this condition,...
-
Product Insights
NewEncephalopathy – Drugs In Development, 2024
Empower your strategies with our Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness. Causes include traumas or injuries, genetics, liver disease, hypoxic condition, Lyme disease, and organ failure. The Encephalopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Encephalopathy,...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...
-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADG-126 in Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADG-126 in Uveal Melanoma Drug Details: ADG-126 is under development for the...
-
Product Insights
Encephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Its symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching, and muscle weakness. The Encephalopathy pipeline market research report provides comprehensive information on the therapeutics under development for Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RLS-0071
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RLS-0071 Drug Details RLS-0071 (PIC1-01) is under development for the treatment of neonatal hypoxic-ischemic...